Latest News

May 22, 2025

ScitoVation Awarded $2.04 Million SBIR Phase II Grant from NIEHS to Advance Predictive Toxicology Technology 

Read More
March 12, 2025

Integral Consulting and ScitoVation Announce Strategic Alliance to Advance Innovation in Health Risk Assessment

Read More
February 18, 2025

ScitoVation Announces Strategic Focus on Computational Toxicology: Laboratory Operations to Conclude March 31, 2025

Read More
Featured image for “Systems PBK/PD Modeling of 4-Hydroxyphenylpyruvate Dioxygenase Inhibition”
October 2, 2024

Systems PBK/PD Modeling of 4-Hydroxyphenylpyruvate Dioxygenase Inhibition

Read More
Featured image for “Integrating computational tools and human cell-based NAMs for human-relevant risk assessments”
September 3, 2024

Integrating computational tools and human cell-based NAMs for human-relevant risk assessments

Read More
Featured image for “Quantitative Interpretation of in vitro Genotoxicity Data for Risk Assessment”
August 13, 2024

Quantitative Interpretation of in vitro Genotoxicity Data for Risk Assessment

Read More
Featured image for “Quantitative Interpretation of Genetic Toxicity Dose-response Data for Risk Assessment and Regulatory Decision-making: Opportunities, Challenges and Future Prospects”
June 19, 2024

Quantitative Interpretation of Genetic Toxicity Dose-response Data for Risk Assessment and Regulatory Decision-making: Opportunities, Challenges and Future Prospects

Read More
Featured image for “Replacing Regulatory Default Assumptions of Linear Extrapolation of Risk with Benchmark Dose for Next Generation Genotoxicity Risk Assessments”
May 22, 2024

Replacing Regulatory Default Assumptions of Linear Extrapolation of Risk with Benchmark Dose for Next Generation Genotoxicity Risk Assessments

Read More
Featured image for “In vitro assessment of electronic nicotine delivery system (ENDS) aerosols”
April 24, 2024

In vitro assessment of electronic nicotine delivery system (ENDS) aerosols

Read More